mRNA transcript therapy

  title={mRNA transcript therapy},
  author={Drew Weissman},
  journal={Expert Review of Vaccines},
  pages={265 - 281}
  • D. Weissman
  • Published 14 January 2015
  • Biology
  • Expert Review of Vaccines
mRNA is the central molecule of all forms of life. It is generally accepted that current life on Earth descended from an RNA world. mRNA, after its first therapeutic description in 1992, has recently come into increased focus as a method to deliver genetic information. The recent solution to the two main difficulties in using mRNA as a therapeutic, immune stimulation and potency, has provided the basis for a wide range of applications. While mRNA-based cancer immunotherapies have been in… 
Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
This manuscript includes a revision of the strategies employed to enhance in vitro transcribed mRNA functionality and efficacy, including the optimization of its stability and translational efficiency, as well as the regulation of its immunostimulatory properties.
mRNA-based therapeutics: powerful and versatile tools to combat diseases
This review comprehensively describes mRNA-based therapeutics, including their principles, manufacture, application, effects, and shortcomings, and highlights the importance of mRNA optimization and delivery systems in successful mRNA therapeutics.
Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences.
  • R. Rhoads
  • Biology
    Methods in molecular biology
  • 2016
This introductory chapter provides background information relevant to the following 20 chapters of this volume that present protocols for these applications of synthetic mRNA.
Nanoscale platforms for messenger RNA delivery.
This review focuses on recent advances, challenges, and future directions in nanoscale platforms designed for mRNA delivery, including lipid and lipid-derived nanoparticles, polymer-based nanop articles, protein derivatives mRNA complexes, and other types of nanomaterials.
Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases.
Materials for non-viral intracellular delivery of messenger RNA therapeutics.
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes.
In vivo validation of a reversible small molecule-based switch for synthetic self-amplifying mRNA regulation.


mRNA as a versatile tool for exogenous protein expression.
Current pre-clinical and clinical studies using RNA-based vectors for immunotherapy, T cell, stem cell as well as gene therapy, and recent developments in the optimization of messenger RNA as vector for modulation of protein expression are reviewed.
Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.
Modified mRNA encoding herpes simplex virus 1-thymidine kinase (HSV1-tk) was systemically delivered to H460 xenograft-bearing nude mice, it was significantly more effective in suppressing tumor growth than pDNA.
Tumor vaccination using messenger RNA: prospects of a future therapy.
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.
While investigating the impact of different structural modifications of RNA molecules on the kinetics of the encoded protein in DCs, components located 3' of the coding region that contributed to a higher transcript stability and translational efficiency were identified.
Potential therapeutic applications of RNA cap analogs.
The medicinal potential of cap analogs in areas, such as cancer treatment, spinal muscular atrophy treatment, antiviral therapy and the improvement of the localization of nucleus-targeting drugs, are highlighted.
Expression of therapeutic proteins after delivery of chemically modified mRNA in mice
In a mouse model of a lethal congenital lung disease caused by a lack of surfactant protein B (SP-B), twice weekly local application of an aerosol of modified SP-B mRNA to the lung restored 71% of the wild-type SP- B expression, and treated mice survived until the predetermined end of the study after 28 days.
Vaccination with messenger RNA (mRNA).
  • S. Pascolo
  • Biology
    Handbook of experimental pharmacology
  • 2008
The structure of mRNA, its possible optimizations for immunization purposes, the different methods of delivery used in preclinical studies, and finally the results of clinical trial where mRNA is the active pharmaceutical ingredient of new innovative vaccines are described.
Synthetic messenger RNA as a tool for gene therapy.
An efficient vectorfree method of mRNA production from polymerase chain reaction-generated DNA templates is reported that can be applied to generate autologous T lymphocytes directed toward malignant cells and conferred powerful cytotoxicity to T cells against CD19+ targets from the same donor.
Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
It is identified that contaminants, including double-stranded RNA, in nucleoside-modified in vitro-transcribed RNA are responsible for innate immune activation and their removal by high performance liquid chromatography results in mRNA that does not induce IFNs and inflammatory cytokines and is translated at 10- to 1000-fold greater levels in primary cells.
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo
5′ mRNA cap analogs are established as yet another module for tuning immunopharmacological properties of recombinant antigen-encoding RNA for vaccination purposes by analyzing the effect of different synthetic 5′ mRNAcap analogs on the kinetics of the encoded protein.